U.S. Markets open in 5 hrs 28 mins

Capstone Therapeutics Corp. (CAPS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.060.00 (0.00%)
At close: 2:05PM EDT
People also watch
MRNAALSEPARDMNOVBSTC

Capstone Therapeutics Corp.

1275 West Washington Street
Suite 104
Tempe, AZ 85281
United States
602-286-5520
http://www.capstonethx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2

Key Executives

NameTitlePayExercisedAge
Mr. John M. Holliman IIIExec. Chairman & CEO51kN/A63
Mr. Leslie M. TaegerSr. VP, CFO and Principal Financial & Accounting Officer79kN/A66
Dr. Randolph C. Steer M.D., Ph.D.Chief Medical Officer & Consultant4kN/A67
Dr. William M. Wardell M.D., Ph.D.Head of Clinical & Regulatory Review BoardN/AN/A78
Ms. Karen StruckInvestor Relations ProfessionalN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Capstone Therapeutics Corp., a biotechnology company, develops and sells novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have been completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Corporate Governance

Capstone Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.